PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
These metrics indicate whether the stock trades cheaply or expensively relative to its fundamentals. Value investors use them to find mispricings—buying stocks that appear undervalued, with solid long-term prospects and limited downside risk.
-3.76
Negative P/E while Biotechnology median is -2.42. Seth Klarman would scrutinize path to profitability versus peers.
1733.11
P/S exceeding 1.5x Biotechnology median of 22.45. Jim Chanos would check for potential multiple compression risks.
3.86
P/B exceeding 1.5x Biotechnology median of 1.89. Jim Chanos would check for potential asset write-down risks.
-18.74
Negative FCF while Biotechnology median P/FCF is -10.24. Seth Klarman would investigate cash flow improvement potential.
-18.74
Negative operating cash flow while Biotechnology median P/OCF is -10.06. Seth Klarman would investigate operational improvement potential.
3.86
Fair value ratio exceeding 1.5x Biotechnology median of 1.92. Jim Chanos would check for valuation bubble risks.
-6.64%
Negative earnings while Biotechnology median yield is -6.36%. Seth Klarman would investigate path to profitability.
-5.34%
Negative FCF while Biotechnology median yield is -4.38%. Seth Klarman would investigate cash flow improvement potential.